Seattle Genetics

Here's Why Seattle Genetics Stock Jumped 25.7% in October
Motley Fool
Thu, 11/7/19 - 10:56 pm
Seattle Genetics
breast cancer
advanced breast cancer
clinical trials
tucatinib
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates
Pharmaforum
Wed, 11/6/19 - 10:18 am
Daiichi Sankyo
Seattle Genetics
breast cancer
AstraZeneca
trastuzumab deruxtecan
Herceptin
Daiichi sues Seattle Genetics over tech used in high-profile ADC
Fierce Biotech
Tue, 11/5/19 - 10:34 am
Daiichi Sankyo
Seattle Genetics
antibody-drug conjugate
AstraZeneca
DS-8201
4 Stocks Battling Breast Cancer
Motley Fool
Sat, 10/26/19 - 02:18 pm
Seattle Genetics
Macrogenics
Merus
Zymeworks
Seattle Genetics' breast cancer drug hits mark in pivotal trial
Fierce Biotech
Mon, 10/21/19 - 10:03 am
Seattle Genetics
clinical trials
HER2+ breast cancer
tucatinib
Here's Why Seattle Genetics Climbed 17.6% in September
Motley Fool
Mon, 10/7/19 - 11:25 pm
Seattle Genetics
ESMO
clinical trials
tucatinib
colorectal cancer
enfortumab vedotin
urothelial cancer
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
Xconomy
Tue, 10/1/19 - 10:29 am
ESMO
PARP inhibitors
prostate cancer
KRAS
Seattle Genetics
AstraZeneca
Merck
GSK
Amgen
breast cancer
Roche
Pfizer
Seattle Genetics makes case it can be more than Adcetris
Biopharma Dive
Mon, 09/30/19 - 12:03 pm
Seattle Genetics
Adcetris
clinical trials
ESMO
enfortumab vedotin
Astellas
tucatinib
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
Fierce Biotech
Sat, 09/28/19 - 04:36 pm
Seattle Genetics
Astellas
enfortumab vedotin
bladder cancer
ESMO
urothelial cancer
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
Sun, 09/22/19 - 11:10 pm
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Seattle Genetics shares rise on strong Adcetris sales, $218M in revenue for Q2
GeekWire
Wed, 07/17/19 - 10:55 am
Seattle Genetics
earnings
The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
Yahoo/Benzinga
Sun, 07/14/19 - 04:09 pm
Merck
relebactam
TapImmune
earnings
JNJ
Seattle Genetics
Abbott Labs
Intuitive Surgical
Mirum Pharmaceuticals
Fulcrum Therapeutics
Genmab
Seattle Genetics drug could provide new option for bladder cancer patients
Biopharma Dive
Mon, 06/3/19 - 11:24 am
Seattle Genetics
ASCO 2019
enfortumab vedotin
urothelial cancer
Seattle Genetics' "Growth Is Tracking Well"
Motley Fool
Tue, 04/30/19 - 05:29 pm
Seattle Genetics
earnings
Seattle Genetics' Adcetris sales fall short yet again
Biopharma Dive
Sun, 04/28/19 - 12:19 pm
Seattle Genetics
earnings
Adcetris
Seattle Genetics CEO Clay Siegall's comp package soars to $18.1M, rivaling Big Pharma chiefs
Endpoints
Mon, 04/22/19 - 11:09 am
Seattle Genetics
Pharma CEOs
executive pay
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Yahoo/Benzinga
Mon, 04/22/19 - 10:34 am
Concert Pharmaceuticals
Horizon Pharma
Edwards Lifesciences
Zimmer Biomet
Genfit
Precision Biosciences
Boston Scientific
AbbVie
Alexion
Bristol-Myers Squibb
Baxter
Biomarin
AtriCure
Biogen
Seattle Genetics
IPOs
earnings
Seattle Genetics' Adcetris Progresses Well Amid Competition
Yahoo/Zacks.com
Fri, 04/12/19 - 10:01 am
Seattle Genetics
Adcetris
relapsed Hodgkin lymphoma
relapsed systemic anaplastic large cell lymphoma
Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody
Endpoints
Thu, 03/28/19 - 10:11 am
Seattle Genetics
Astellas
enfortumab vedotin
bladder cancer
As generic competition stutter sales of top oncology drugs, Roche secures speedy review for pair of experimental cancer offerings
Endpoints
Tue, 02/19/19 - 12:15 pm
Roche
Seattle Genetics
generics
antibody-drug conjugate
polatuzumab vedotin
relapsed or refractory diffuse large B-cell lymphoma
entrectinib
solid tumors

Pages